Radiopharm Theranostics Limited Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Justin Walsh has given his Buy rating due to a combination of factors related to Radiopharm Theranostics Limited’s promising clinical developments and strategic growth potential. The company is on track with multiple Phase I trials, including Lu-177-RAD204 targeting PD-L1 and Lu-177-RAD202 focusing on HER2, both of which are expected to provide significant data readouts in the second half of 2025. These trials, if successful, could validate the company’s innovative approach using nanobody targeting vectors and its emphasis on validated molecular targets.
Additionally, Radiopharm’s strategic plans to initiate new trials, such as the Phase I therapeutic trial of Lu-177-RV-01 in solid tumors, highlight its commitment to expanding its therapeutic portfolio. The company’s investment thesis is further strengthened by its diverse pipeline of imaging and therapeutic radiopharmaceutical agents, which offer potential for medium- to long-term growth and opportunities for non-dilutive capital through partnerships. The underappreciated potential of assets like RAD101 and RAD204 could significantly enhance the company’s value, especially if favorable clinical data emerges.
Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Actinium Pharmaceuticals, and Y-Mabs Therapeutics. According to TipRanks, Walsh has an average return of -2.5% and a 31.62% success rate on recommended stocks.
In another report released on July 21, Brookline Capital Markets also initiated coverage with a Buy rating on the stock with a $18.00 price target.